Statistical methods in immunology & rheumatology trials
The methods these trials rely on most, based on the statistical analyses posted to ClinicalTrials.gov, with the tutorial that explains each one.
ANCOVA
Odds ratio
Multiple imputation / missing data
Cochran-Mantel-Haenszel test
Mixed-effects model
Logistic regression
MMRM (mixed model for repeated measures)
Risk difference
All immunology & rheumatology trials
1,062 results
- Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL): Complete Statistical AnalysisIndependent statistical analysis of Bendamustine Plus Rituximab (BR) for Relapsed or Progressive Marginal Zone B-cell Lymphoma (MZBCL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients: Complete Statistical AnalysisIndependent statistical analysis of Benefits of Injectable Abatacept Using Magnetic Resonance Imaging (MRI) in Rheumatoid Arthritis (RA) Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BESPOKEIndependent statistical analysis of A Study of the Efficacy and Safety of MEDI7352 in Participants With Painful Osteoarthritis of the Knee: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- BESTFITIndependent statistical analysis of BEdtime Sublingual TNX-102 SL as Fibromyalgia Intervention Therapy (BESTFIT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01903265).
- BeyondComplete statistical analysis of the Beyond phase 3 trial of interferon beta-1b in relapsing-remitting multiple sclerosis, including trial design, registered endpoints, safety analyses, confidence intervals, and statistical interpretation.
- BFR-MSIndependent statistical analysis of Low Load Resistance Training Using Blood Flow Restriction for People With Multiple Sclerosis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BGIndependent statistical analysis of Effects of Orally Administered Beta-glucan on Leukocyte Function in Humans: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01727895).
- BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of BI 695500 vs Rituxan First Line Treatment in Patients With Low Tumor Burden Follicular Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL): Complete Statistical AnalysisIndependent statistical analysis of BI836826 Dose Escalation in Relapsed Chronic Lymphocytic Leukaemia (CLL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01296932).
- BIANCAIndependent statistical analysis of Phase II Open Label Trial to Determine Safety & Efficacy of Tisagenlecleucel in Pediatric Non-Hodgkin Lymphoma Patients: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration,…
- Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men: Complete Statistical AnalysisIndependent statistical analysis of Biobehavioral Interventions for HIV-negative, Stimulant Using Men Who Have Sex With Men: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- BioCSI-2Independent statistical analysis of Biomarkers of Cockroach Sublingual Immunotherapy 2: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01380327).
- Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor: Complete Statistical AnalysisIndependent statistical analysis of Biparental HLA Haplotype Disparate T-cell Depleted Transplants for Patients Lacking an HLACompatible Donor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BK Treatment Study: Complete Statistical AnalysisIndependent statistical analysis of BK Treatment Study: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01034176).
- Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts: Complete Statistical AnalysisIndependent statistical analysis of Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow Lymphoblasts: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia: Complete Statistical AnalysisIndependent statistical analysis of Blinatumomab in Treating Younger Patients With Relapsed B-cell Acute Lymphoblastic Leukemia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia: Complete Statistical AnalysisIndependent statistical analysis of Blinded Randomized Placebo-Controlled Study Efficacy and Safety of Injectafer in ID Patients With Fibromyalgia: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis: Complete Statistical AnalysisIndependent statistical analysis of Blinded Study of Topical Investigational Lotion Vs. Approved Cream in Treatment of Plaque Psoriasis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BLIR-HIVIndependent statistical analysis of Bone Loss and Immune Reconstitution in HIV/AIDS (BLIR-HIV): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01228318).
- Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor: Complete Statistical AnalysisIndependent statistical analysis of Bone Marrow Transplantation of Patients in Remission Using Partially Matched Relative Donor: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov…
- Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen: Complete Statistical AnalysisIndependent statistical analysis of Bone Mineral Density in Human Immunodeficiency Virus Type 1 (HIV-1)-Infected Adult Subjects Switching From a Tenofovir Regimen to a Dolutegravir Plus Rilpivirine Regimen: primary endpoint results, effect estimate…
- BOOST™Independent statistical analysis of Comparison of NN5401 Plus Insulin Aspart With Insulin Detemir Plus Insulin Aspart in Type 1 Diabetes: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- BOREASIndependent statistical analysis of Crossover Trial to Assess Efficacy and Safety of Inhaled AQ001S Compared to a Budesonide Suspension in Mild Asthmatics: primary endpoint results, effect estimate with confidence interval, sample-size planning…
- Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and…
- Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00869323).
- Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00075881).
- Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL): Complete Statistical AnalysisIndependent statistical analysis of Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00440726).
- Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence…
- Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin’s Lymphoma That is Recurrent or Did Not Respond to Previous Therapy: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy: primary endpoint results, effect estimate with…
- Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis: Complete Statistical AnalysisIndependent statistical analysis of Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis:…
- BOSTON-4Independent statistical analysis of A Safety Study of Liposomal Cyclosporine A to Treat Bronchiolitis After Hematopoietic Transplant (BOSTON-4): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based…
- BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis: Complete Statistical AnalysisIndependent statistical analysis of BOTOX® Efficacy and Safety in the Treatment of Knee Osteoarthritis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT02230956).
- Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint: Complete Statistical AnalysisIndependent statistical analysis of Botulism Toxin Injection as a Treatment for Arthritis of the Basal Thumb Joint: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BRAVOComplete statistical analysis of the BRAVO phase 3 trial of laquinimod in participants with relapsing-remitting multiple sclerosis, including its annualized confirmed relapse-rate analysis, negative binomial regression methodology, confidence intervals, and statistical interpretation.
- BREEZE-AD1Independent statistical analysis of A Study of Baricitinib (LY3009104) in Patients With Moderate to Severe Atopic Dermatitis: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BretuximabIndependent statistical analysis of Brentuximab Vedotin in Patients With Relapsed or Refractory EBV-and CD30-positive Lymphomas: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BRPIndependent statistical analysis of IIT CTI Bendamustine, Rituximab, Pixantrone in Relapsed/Refractory B Cell Non-Hodgkin's Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results…
- BRUOG-407Independent statistical analysis of Removing Transfusion Dependence as a Barrier to Hospice Enrollment: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT05063591).
- BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL): Complete Statistical AnalysisIndependent statistical analysis of BTK Inhibitor BGB-3111 in Chinese Participants With Diffuse Large B-Cell Lymphoma (Non-GCB) and Indolent Lymphoma (FL and MZL): primary endpoint results, effect estimate with confidence interval, sample-size planning…
- BudERIndependent statistical analysis of Effect of Nebulized Budesonide and Oral Corticosteroids on Wheezing Episode Relapse in Children: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- Busulfan and Cyclophosphamide Followed By ALLO BMT: Complete Statistical AnalysisIndependent statistical analysis of Busulfan and Cyclophosphamide Followed By ALLO BMT: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT01685411).
- Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide: Complete Statistical AnalysisIndependent statistical analysis of Busulfan and Fludarabine Followed by Post-transplant Cyclophosphamide: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00800839).
- Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT): Complete Statistical AnalysisIndependent statistical analysis of Busulfan Safety/Efficacy as Conditioning Prior to Hematopoietic Cell Transplantation (HCT): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00361140).
- Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies: Complete Statistical AnalysisIndependent statistical analysis of Busulfan-fludarabine Conditioning and T-cell Depleted Allogeneic Stem Cell Transplantation for Patients With Advanced Hematologic Malignancies: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety,…
- Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma: Complete Statistical AnalysisIndependent statistical analysis of Busulfan, Cyclophosphamide, and Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma: Complete Statistical AnalysisIndependent statistical analysis of BV-CHEP Chemotherapy for Adult T-cell Leukemia or Lymphoma: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT03264131).
- C_ASCENTIndependent statistical analysis of Evaluating the Safety and Effectiveness of Interferon-Free Treatment of Hepatitis C Virus Infection in HIV-Coinfected Adults on Antiretroviral Therapy: primary endpoint results, effect estimate with confidence interval, sample-size…
- C-earlyIndependent statistical analysis of A Multi-center, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Efficacy and Safety of Certolizumab Pegol in Combination With Methotrexate in the Treatment of Disease Modifying Antirheumatic Drugs (DMARD)-naïve…
- C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks: Complete Statistical AnalysisIndependent statistical analysis of C1 Esterase Inhibitor (C1INH-nf) for the Treatment of Acute Hereditary Angioedema (HAE) Attacks: primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on…
- C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study): Complete Statistical AnalysisIndependent statistical analysis of C1 Esterase Inhibitor in Hereditary Angioedema (HAE)(Extension Study): primary endpoint results, effect estimate with confidence interval, sample-size planning illustration, and safety, based on ClinicalTrials.gov results (NCT00292981).